CRBP vs. ARCT, MBX, CMPX, HUMA, PRTA, HRTX, TERN, AMRN, PRME, and AQST
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Arcturus Therapeutics (ARCT), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Terns Pharmaceuticals (TERN), Amarin (AMRN), Prime Medicine (PRME), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs. Its Competitors
Arcturus Therapeutics (NASDAQ:ARCT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.
Corbus Pharmaceuticals has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.05, indicating that its share price is 205% more volatile than the S&P 500.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Arcturus Therapeutics had 6 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 7 mentions for Arcturus Therapeutics and 1 mentions for Corbus Pharmaceuticals. Arcturus Therapeutics' average media sentiment score of 1.01 beat Corbus Pharmaceuticals' score of 0.04 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Arcturus Therapeutics presently has a consensus target price of $54.00, indicating a potential upside of 296.48%. Corbus Pharmaceuticals has a consensus target price of $50.88, indicating a potential upside of 556.45%. Given Corbus Pharmaceuticals' higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Arcturus Therapeutics.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Corbus Pharmaceuticals' return on equity.
Summary
Arcturus Therapeutics beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 7/3/2025 by MarketBeat.com Staff
